Where does Istituto Europeo di Oncologia S.r.l. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Istituto Europeo di Oncologia S.r.l. ranks #29,140 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Istituto Europeo di Oncologia S.r.l. hold?

Istituto Europeo di Oncologia S.r.l. holds 9 US utility patents granted between 2018 and 2024, spanning 6 technology areas.

What is Istituto Europeo di Oncologia S.r.l.'s Innovation Score?

Istituto Europeo di Oncologia S.r.l. has an Innovation Score of 33.3 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Istituto Europeo di Oncologia S.r.l.'s patent grant rate increasing or decreasing?

Istituto Europeo di Oncologia S.r.l.'s recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Istituto Europeo di Oncologia S.r.l.'s patents?

Istituto Europeo di Oncologia S.r.l.'s patents average 21.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Istituto Europeo di Oncologia S.r.l. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Istituto Europeo di Oncologia S.r.l.

Q: What technology areas does Istituto Europeo di Oncologia S.r.l. focus on?

Istituto Europeo di Oncologia S.r.l.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Istituto ranks #29,140 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#29,140
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.3/100): 21.1
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29140 · Foreign Corporation #29,140 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,140/49,997
PHOTO-FINISH Invent Medical…
CPC-NARROW A61P · 6 areas
INNOV-THIN 33.3/100
CLAIMS-DENSE 21.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Invent Medical Group, s.r.o. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Istituto Europeo di… · this assignee

33
3D Lighting… · lowest

7

What this shows Istituto's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Istituto's grants concentrate

Istituto Europeo di Oncologia S.r.l. is a focused PatentsView assignee: 6 CPC subclasses with 77.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2018. By volume, Istituto sits between Invent Medical Group, s.r.o. and J-mex Inc..

Istituto's three-year grant acceleration

Istituto Europeo di Oncologia S.r.l. shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Invent Medical Gr…

9
Invisalert Soluti…

9
Iron Cross Automo…

9
Isofol Medical AB

9
Ivys

9
J-fiber

9
J-lok

9
J-mex

9
Istituto Europeo… ◀

9

What this shows Istituto holds 9 patents at rank #29,120, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Istituto

By rank, the assignees closest to #29,120 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Istituto's primary technology class.

Istituto's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Istituto Europeo di Oncologia S.r.l. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	11.1%
2019	2	22.2%
2020	1	11.1%
2021	2	22.2%
2022	1	11.1%
2024	2	22.2%

Which technologies does Istituto Europeo di Oncologia S.r.l. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C07D - Heterocyclic Compounds 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 2

C07C - Acyclic OR Carbocyclic Compounds 1

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#29,140

of 49,997 tracked assignees

Innovation Score

33.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Istituto Europeo di Oncologia S.r.l.'s patent record in context - here's where to go next.

Istituto Europeo di Oncologia S.r.l.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 77.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #29,140 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Istituto Europeo di Oncologia S.r.l. against Invent Medical Group, s.r.o., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.